Clinical practice experience with pangenotypic therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir; data from the TRIO Network

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


Clinical practice experience with pangenotypic therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir; data from the TRIO Network

	Reported by Jules Levin EASL 2019 April 10-14 Vienna